Albireo’s Bylvay approved in EU and US for rare paediatric liver disease
PFIC is a rare and progressive liver disease affecting young children which can lead to cirrhosis and liver failure
Read More
Tag: Albireo Pharma
Albireo submits rare liver disease med odevixibat to FDA and EMA
If approved, drug will become first treatment for PFIC patients in the US and EU
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
